·AIM: To investigate the efficacy of intravitreal injection of Conbercept in the treatment of diabetic macular edema (DME). ·METHODS: Totally 95 patients(95 eyes) with diabetic macular edema treated in our hospital from January 2014 to December 2016 were retrospectively analyzed, and 42 cases received Ranibizumab intravitreal injection were included into control group, 53 cases treated with conbercept intravitreal injection were included into observation group. The changes of preoperative and postoperative follow up visual acuity and macular foveal thickness in the two groups were observed. The repeated medication, complications and medical expenses were also compared. ·RESULTS:The preoperative best corrected visual acuity between groups showed no difference (P>0. 01). The postoperative best corrected visual acuity between groups showed distinct difference (F = 105. 326, P0. 05). At 6mo after operation,the observation group's visual acuity was evidently higher than that at 3mo (P0.05). The overall changes of foveal thickness between two groups showed a significant difference (F=86.365, P0.05). The repeated medication of observation group during the postoperative 1,3 and 6mo of followed up was evidently less than that of the control group,the difference between groups was significant (P0. 05). The average medical cost of the observation group was obviously less than that of the control group,and the difference between the two groups was evident (P0.05).两组患者不同时间BCVA比较,差异有统计学意义(F=105.326,P0.05).观察组治疗后6mo BCVA较治疗后3mo提高,差异有统计学意义(P0.05).组间治疗后6mo比较差异有统计学意义(P0.05),不同时间两组患者黄斑中心凹厚度比较,差异有统计学意义(F=86.365,P0.05).随访期间观察组重复用药次数均较对照组少,差异均有统计学意义(P0.05);观察组平均医疗费用明显较对照组低,差异有统计学意义(P<0.01).结论:玻璃体腔注射康柏西普治疗DME,可有效改善黄斑水肿,提高视力,且药效持久,价格低廉,安全性高.
展开▼
